These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10970686)

  • 1. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
    Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
    Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor markers and
    Dondi F; Albano D; Bertagna F; Giubbini R
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
    Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
    Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
    J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
    Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Partridge SE; Huddart RA
    Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
    De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
    Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
    J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
    Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
    Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
    Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM
    Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.
    Sugawara Y; Zasadny KR; Grossman HB; Francis IR; Clarke MF; Wahl RL
    Radiology; 1999 Apr; 211(1):249-56. PubMed ID: 10189480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.